Evidence map›Paper›PMID 23921086›Full record

ArticleScience signaling2013

Interference with akt signaling protects against myocardial infarction and death by limiting the consequences of oxidative stress.

Bethany A Kerr, Lining Ma, Xiaoxia Z West, Liang Ding, Nikolay L Malinin, Malory E Weber, Mira Tischenko, Anna Goc, Payaningal R Somanath, Marc S Penn and 2 more

Open access · greenAbstract read
In one paragraph

Article in Science signaling, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?American journal of physiology. Lung cellular and molecular physiology · 2020
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Bethany A KerrDepartment of Molecular Cardiology, Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Lining Ma
Xiaoxia Z West
Liang Ding
Nikolay L Malinin
Malory E Weber
Mira Tischenko
Anna Goc
Payaningal R Somanath
Marc S Penn
Eugene A Podrez
Tatiana V Byzova
Cleveland Clinic Lerner College of Medicine · USJacobs (United States) · USCharlie Norwood VA Medical Center · USNortheast Ohio Medical University · USUniversity of Georgia · US

Funding

Regulation of Integrins in Neovasculature DevelopmentR01HL071625 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI BYZOVA, TATIANA V · 2003 to 2021
$7.3M
Pathophysiological Activities of Oxidized PhospholipidsR01HL077213 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI PODREZ, EUGENE A · 2005 to 2018
$4.5M
Protein kinase B (Akt)-mediated pathway regulating endothelial-barrier functionR01HL103952 · NHLBI · UNIVERSITY OF GEORGIA · PI SHENOY, SOMANATH P RAMMOHAN · 2011 to 2015
$1.5M
Integrins and bone matrix in prostate cancerR01DK060933 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI BYZOVA, TATIANA V · 2003 to 2006
$1.1M
Molecular Mechanisms of Prostate Cancer Induced Bone RemodelingF32CA142133 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI KERR, BETHANY AMBER · 2010 to 2013
$116k
NCI NIH HHS F32 CA142133NHLBI NIH HHS R01 HL071625NHLBI NIH HHS R01 HL077213NHLBI NIH HHS R01 HL103952NIDDK NIH HHS R01 DK060933
6 · The paper itself

Abstract

The intricacy of multiple feedback loops in the pathways downstream of Akt allows this kinase to control multiple cellular processes in the cardiovascular system and precludes inferring consequences of its activation in specific pathological conditions. Akt1, the major Akt isoform in the heart and vasculature, has a protective role in the endothelium during atherosclerosis. However, Akt1 activation may also have detrimental consequences in the cardiovascular system. Mice lacking both the high-density lipoprotein receptor SR-BI (scavenger receptor class B type I) and ApoE (apolipoprotein E), which promotes clearance of remnant lipoproteins, are a model of severe dyslipidemia and spontaneous myocardial infarction. We found that Akt1 was activated in these mice, and this activation correlated with cardiac dysfunction, hypertrophy, and fibrosis; increased infarct area; cholesterol accumulation in macrophages and atherosclerosis; and reduced life span. Akt1 activation was associated with inflammation, oxidative stress, accumulation of oxidized lipids, and increased abundance of CD36, a major sensor of oxidative stress, and these events created a positive feedback loop that exacerbated the consequences of oxidative stress. Genetic deletion of Akt1 in this mouse model resulted in decreased mortality, alleviation of multiple complications of heart disease, and reduced occurrence of spontaneous myocardial infarction. Thus, interference with Akt1 signaling in vivo could be protective and improve survival under dyslipidemic conditions by reducing oxidative stress and responses to oxidized lipids.

Indexed as

Oxidative StressSignal TransductionAnimalsApolipoproteins EAtherosclerosisCD36 AntigensDisease Models, AnimalEnzyme ActivationMiceMice, KnockoutMyocardial InfarctionProto-Oncogene Proteins c-aktScavenger Receptors, Class BAkt1 protein, mouseApolipoproteins ECD36 AntigensProto-Oncogene Proteins c-aktSCARB1 protein, humanScavenger Receptors, Class B

Identifiers

PMID23921086
PMCPMC3971949
OpenAlexW2152575820

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.